Abstract:The HIV-1 transactivator protein Tat interacts with the transactivation response element (TAR) at the three-nucleotide UCU bulge to facilitate the recruitment of transcription elongation factor-b (P-TEFb) and induce the transcription of the integrated proviral genome. Therefore, the Tat–TAR interaction, unique to the virus, is a promising target for developing antiviral therapeutics. Currently, there are no FDA-approved drugs against HIV-1 transcription, suggesting the need to develop novel inhibitors that specifically target HIV-1 transcription. We have identified potential candidates that effectively inhibit viral transcription in myeloid and T cells without apparent toxicity. Among these candidates, two molecules showed inhibition of viral protein expression. A molecular docking and simulation approach was used to determine the binding dynamics of these small molecules on TAR RNA in the presence of the P-TEFb complex, which was further validated by a biotinylated RNA pulldown assay. Furthermore, we examined the effect of these molecules on transcription factors, including the SWI/SNF complex (BAF or PBAF), which plays an important role in chromatin remodeling near the transcription start site and hence regulates virus transcription. The top candidates showed significant viral transcription inhibition in primary cells infected with HIV-1 (98.6). Collectively, our study identified potential transcription inhibitors that can potentially complement existing cART drugs to address the current therapeutic gap in current regimens. Additionally, shifting of the TAR RNA loop towards Cyclin T1 upon molecule binding during molecular simulation studies suggested that targeting the TAR loop and Tat-binding UCU bulge together should be an essential feature of TAR-binding molecules/inhibitors to achieve complete viral transcription inhibition.

Design and Synthesis of Guanidinoglycosides Directed Against the TAR RNA of HIV‐1

Alpha,Alpha-Trehalose Derivatives Bearing Guanidino Groups As Inhibitors to Hiv-1 Tat-Tar Rna Interaction in Human Cells

TAR RNA selective targeting ruthenium(II) complexes as HIV-1 reverse transcriptase inhibitors: On exploring structure-activity relationships of multiple positions

Synthesis and Anti‐HIV Activity of a Series of 6‐modified 2′,3′‐dideoxyguanosine and 2′,3′‐didehydro‐2′,3′‐dideoxyguanosine Analogs

Co-crystal structures of HIV TAR RNA bound to lab-evolved proteins show key roles for arginine relevant to the design of cyclic peptide TAR inhibitors

Terpyridyl ruthenium complexes as visible spectral probe for poly(A) RNA and bifunctional TAR RNA binders and HIV-1 reverse transcriptase inhibitors

The synthesis of 2'-O-methyl G-clamp containing oligonucleotides and their inhibition of the HIV-1 Tat-TAR interaction

HIV-1 Transcription Inhibition Using Small RNA-Binding Molecules.

1,2,3-Thiadiazole Thioacetanilides As a Novel Class of Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors.

Selective Small Molecules Blocking HIV-1 Tat and Coactivator PCAF Association.

Quinazolinone-based subchemotypes for targeting HIV-1 capsid protein: design and synthesis

Design and synthesis of Fsp3‐enriched spirocyclic‐substituted diarylpyrimidine derivatives as novel HIV‐1 NNRTIs

The Prodrugs of L-guanosine Analogs: Design, Synthesis and Anti-Hiv Activity

Design, Synthesis and Biological Evaluation of 3-Substituted 2,5-Dimethyl-n-(3-(1h-tetrazol-5-yl)phenyl)pyrroles As Novel Potential HIV-1 Gp41 Inhibitors

Design, synthesis, and biological evaluation of benzo[4,5]thieno[2,3- d ]pyrimidine derivatives as novel HIV-1 NNRTIs

Design and Biological Evaluation of M-Xylene Thioether-Stapled Short Helical Peptides Targeting the HIV-1 Gp41 Hexameric Coiled-Coil Fusion Complex.

Design of Biphenyl-Substituted Diarylpyrimidines with a Cyanomethyl Linker as HIV-1 NNRTIs via a Molecular Hybridization Strategy.

Design of Tat-Activated Cdk9 Inhibitor

Small molecule fusion inhibitors: design, synthesis and biological evaluation of (Z)-3-(5-(3-benzyl-4-oxo-2-thioxothiazolidinylidene)methyl)-N-(3-carboxy-4-hydroxy)phenyl-2,5-dimethylpyrroles and related derivatives targeting HIV-1 gp41.

Synthesis, Biological Evaluation and Molecular Docking Study of N-(2-methoxyphenyl)-6-((4-nitrophenyl)sulfonyl)benzamide Derivatives As Potent HIV-1 Vif Antagonists.

Design and Synthesis of New GS-6207 Subtypes for Targeting HIV-1 Capsid Protein